Nirsevimab vs Palivizumab: 3‑Season Analysis of Hospital Admission Rates and LOS for High‑Risk Infants < 20 months in a Federally Qualified Health Center NICU Follow‑Up Clinic

Anne F. Kay, Denver Health Hospital Authority, Denver, CO, United States; Philip Miller, University of Colorado School of Medicine, Denver, CO, United States; Cassana Littler, Denver Health & Hospital Authority; University of Colorado School of Medicine, Morrison, CO, United States